


Primary endpoint: Proportion of patients with transfusion independence (TI) for ≥8 consecutive weeks in the first 28 treatment weeks **Eligibility:** Baseline serum erythropoietin ≤400 mIU/mL and a low packed RBC transfusion burden

TRIAL DESIGN Intervention



EFFICACY

